# US 2026/0151483 A1 · Gucy2c t cell-antigen couplers and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0151483 A1
- Document ID: US20260151483A1
- Status: Published application
- Kind: A1
- Application number: 19/259,331
- Filed: 2025-07-03
- Published: 2026-06-04
- Earliest claimed: 2021-07-08
- Assignees: Triumvira Immunologics USA, Inc.
- Applicants: Triumvira Immunologics USA, Inc.
- Inventors: Andreas Bader; Christopher W. Helsen; Philbert Ip; Tania Benatar
- Web page: https://patentgrep.com/patent/US20260151483A1

## CPC

- A61K 40/4244: {Enzymes}
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/32: T-cell receptors [TCR]
- A61P 35/00: Antineoplastic agents
- C07K 14/7051: {T-cell receptor (TcR)-CD3 complex}
- C07K 14/70514: {CD4}
- C07K 16/40: against enzymes
- C12Y 406/01002: Guanylate cyclase (4.6.1.2)
- A61K 2039/505: {comprising antibodies}
- A61K 2239/31: characterized by the route of administration
- A61K 2239/38: characterised by the dose, timing or administration schedule
- A61K 2239/50: Colon
- C07K 2317/21: from primates, e.g. man
- C07K 2317/22: from camelids, e.g. camel, llama or dromedary
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/569: Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2317/70: characterized by effect upon binding to a cell or to an antigen
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K 2319/03: containing a transmembrane segment
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C07K 2319/70: containing domain for protein-protein interaction
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12Y: ENZYMES

## Abstract

GUCY2C T cell antigen coupler (TAC) polypeptides having (i) an antigen-binding domain that binds GUCY2C, (ii) an antigen-binding domain that binds a protein associated with a TCR complex, and (iii) a T cell receptor signaling domain polypeptide are provided.

## Claims

### Claim 1

A Guanylate Cyclase 2C (GUCY2C) T cell-antigen coupler (GUCY2C-TAC) protein, comprising:
(a) a first polypeptide encoding an antigen-binding domain that binds GUCY2C, wherein:
i) the GUCY2C antigen-binding domain comprises a heavy chain variable region comprising (a) a CDR1 having an amino acid sequence selected from the group consisting of SEQ ID NO: 204, 210, 216, 222, 228, 234, 240, 246, 252, 258, 264, 270, 276, 282, 288, 294, 300, 306, 312, 318, 324, 330, 336, 342, 348, 354, 393, 399, 405, 411, 417, 423, 429, 435, 441, 447, 453, 459, 522, 525, 528, 531, 534, 537, 540, and 543, (b) a CDR2 having an amino acid sequence selected from the group consisting of SEQ ID NO: 205, 211, 217, 223, 229, 235, 241, 247, 253, 259, 265, 271, 277, 283, 289, 295, 301, 307, 313, 319, 325, 331, 337, 343, 349, 355, 394, 400, 406, 412, 418, 424, 430, 436, 442, 448, 454, 460, 523, 526, 529, 532, 535, 538, 541, and 544, and (c) a CDR3 having an amino acid sequence selected from the group consisting of SEQ ID NO: 206, 212, 218, 224, 230, 236, 242, 248, 254, 260, 266, 272, 278, 284, 290, 296, 302, 308, 314, 320, 326, 332, 338, 344, 350, 356, 395, 401, 407, 413, 419, 425, 431, 437, 443, 449, 455, 461, 524, 527, 530, 533, 536, 539, 542, and 545; and a light chain variable region comprising (a) a CDR1 having an amino acid sequence selected from the group consisting of SEQ ID NO: 207, 213, 219, 225, 231, 237, 243, 249, 255, 261, 267, 273, 279, 285, 291, 297, 303, 309, 315, 321, 327, 333, 339, 345, 351, 357, 396, 402, 408, 414, 420, 426, 432, 438, 444, 450, 456 and 462, (b) a CDR2 having an amino acid sequence selected from the group consisting of SEQ ID NO: 208, 214, 220, 226, 232, 238, 244, 250, 256, 262, 268, 274, 280, 286, 292, 298, 304, 310, 316, 322, 328, 334, 340, 346, 352, 358, 397, 403, 409, 415, 421, 427, 433, 439, 445, 451, 457 and 463, and (c) a CDR3 having an amino acid sequence selected from the group consisting of SEQ ID NO: 209, 215, 221, 227, 233, 239, 245, 251, 257, 263, 269, 275, 281, 287, 293, 299, 305, 311, 317, 323, 329, 335, 341, 347, 353, 359, 398, 404, 410, 416, 422, 428, 434, 440, 446, 452, 458 and 464; or
ii) the GUCY2C antigen-binding domain is a nanobody and comprises (a) a VHH CDR1 having an amino acid sequence selected from the group consisting of SEQ ID NO: 360, 363, 366, 369, 372, 375, 378, 381, 384, 387, and 390: (b) a VHH CDR2 having an amino acid sequence selected from the group consisting of SEQ ID NO: 361, 364, 367, 370, 373, 376, 379, 382, 385, 388, and 391; and (c) a VHH CDR3 having an amino acid sequence selected from the group consisting of SEQ ID NO: 362, 365, 368, 371, 374, 377, 380, 383, 386, 389, and 392:
(b) a second polypeptide encoding an antigen-binding domain that binds a protein associated with a TCR complex; and
(c) a third polypeptide encoding a TCR co-receptor cytosolic domain and transmembrane domain;
wherein components encoded by (a), components encoded by (b), and components encoded by (c) are fused directly to each other, or joined by at least one linker.

### Claim at position 2

2-5. (canceled)

### Claim 6 (depends on 1)

The GUCY2C-TAC protein of claim 1, wherein the protein associated with the TCR complex is a CD3 protein.

### Claim at position 4

-9. (canceled)

### Claim 10 (depends on 1)

The GUCY2C-TAC protein of claim 1, wherein the antigen-binding domain that binds the protein associated with the TCR complex is derived from an antibody selected from UCHT1, OKT3, F6A, and L2K.

### Claim at position 6

-15. (canceled)

### Claim 16 (depends on 10)

The GUCY2C-TAC protein of claim 10, wherein antigen-binding domain that binds the protein associated with the TCR complex comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity with SEQ ID NO: 32 (UCHT1), SEQ ID NO: 44 (UCHT1 (Y182T)), SEQ ID NO: 40 (huUCHT1), or SEQ ID NO: 42 (huUCHT1 (Y177T)).

### Claim at position 8

-30. (canceled)

### Claim 31 (depends on 1)

The GUCY2C-TAC protein of claim 1, wherein the transmembrane domain is a CD4 transmembrane domain and the cytosolic domain is a CD4 cytosolic domain.

### Claim at position 10

-33. (canceled)

### Claim 34 (depends on 1)

The GUCY2C-TAC protein of claim 1, wherein the component encoded by (a) and the component encoded by (c) are fused to the component encoded by (b).

### Claim 35 (depends on 1)

The GUCY2C-TAC protein of claim 1, wherein the component encoded by (b) and the component encoded by (c) are fused to the component encoded by (a).

### Claim 36 (depends on 1)

The GUCY2C-TAC protein of claim 1, wherein at least one linker joins the component encoded by (a) to the component encoded by (b).

### Claim at position 14

-38. (canceled)

### Claim 39 (depends on 1)

The GUCY2C-TAC protein of claim 1, wherein the GUYC2C antigen binding domain is selected from an amino acid sequence according to any one of SEQ ID NOs: 53-127 or 514-521.

### Claim 40 (depends on 1)

The GUCY2C-TAC protein of claim 1, wherein the GUCY2C antigen-binding domain comprises a heavy chain variable region having an amino acid sequence having at least 80% sequence identity with an amino acid sequence according to any one of SEQ ID NOs: 128, 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 162, 164, 166, 168, 170, 172, 174, 176, 178, 180, 182, 184, 186, 188, 190, 192, 194, 196, 198, 200, and 202; and a light chain variable region having an amino acid sequence having at least 80% sequence identity with an amino acid sequence according to any one of SEQ ID NOs: 129, 131, 133, 135, 137, 139, 141, 143, 145, 147, 149, 151, 153, 155, 157, 159, 161, 163, 165, 167, 169, 171, 173, 175, 177, 179, 181, 183, 185, 187, 189, 191, 193, 195, 197, 199, 201, and 203.

### Claim at position 17

-47. (canceled)

### Claim 48

A GUCY2C TAC protein comprising an amino acid sequence having at least 80% sequence identity with the amino acid sequence of any one of SEQ ID NOs: 465-513, 546-590, or 686.

### Claim 49

(canceled)

### Claim 50 (depends on 1)

A nucleic acid sequence encoding the GUCY2C TAC protein of claim 1.

### Claim at position 21

-53. (canceled)

### Claim 54 (depends on 50)

A T cell comprising the nucleic acid sequence of claim 50.

### Claim 55 (depends on 54)

A pharmaceutical composition comprising the T cell of claim 54, and a pharmaceutically acceptable excipient.

### Claim 56 (depends on 55)

A method of treating a GUCY2C-expressing cancer in an individual in need thereof, comprising administering to the individual the pharmaceutical composition of claim 55.

### Claim 57 (depends on 56)

The method of claim 56, wherein the cancer is a solid cancer.

### Claim 58 (depends on 56)

The method of claim 56, wherein the cancer is a primary colorectal cancer, a primary gastric cancer, a primary gastroesophageal junction cancer, a primary esophageal cancer, or a primary pancreatic cancer.

### Claim 59 (depends on 56)

The method of claim 56, wherein the cancer is a metastatic colorectal cancer, a metastatic gastric cancer, a metastatic gastroesophageal junction cancer, a metastatic esophageal cancer, or a metastatic pancreatic cancer.

### Claim 60 (depends on 1)

The GUCY2C TAC protein of claim 1, wherein the first polypeptide encoding the antigen-binding domain that binds GUCY2C comprises the VHH CDR1 having an amino acid sequence according to SEQ ID NO: 366, the VHH CDR2 having an amino acid sequence according to SEQ ID NO: 367, and the VHH CDR3 having an amino acid sequence according to SEQ ID NO: 368.

### Claim 61 (depends on 48)

The GUCY2C TAC protein of claim 48, comprising an amino acid sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 569.
